Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
By E. Perez, E. Romond, V. Suman, Jong-Hyeon Jeong, N. Davidson, C. Geyer, S. Martino, E. Mamounas, P. Kaufman, N. Wolmark. Journal of Clinical Oncology, 2011
721 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/fef293c14d8655a64fb2867b97022948799e1fad
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013, background): “Since 2005, several of the first-generation adjuvant trials have been updated and have confirmed the disease-free and overall survival benefit offered by 1 year of trastuzumab administered with or after adjuvant chemotherapy.(29-31) Prospective randomized trials, first reported in abstract form in l”
- Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. (2014, methodology): “Proportional hazards modeling was used to assess whether DFS or OS differed with respect to treatment, taking into account the stratification factors: study (B-31 v N9831), intended paclitaxel schedule (once every 3 weeks v once per week), number of positive nodes (zero to three v four to nine v 10 ”